Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekBioPharma Dive ↗
The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the …
DealsBriefing
The pharma giant’s latest acquisitions of Curevo, LimmaTech, and Vaccine Company reinforce its pivot from trea…
The WeekFiercePharma ↗
The layoffs at AbbVie's Irvine, California, location will take effect on July 20, according to a recent WARN n…
The WeekFierceBiotech ↗
Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it picked up from Ver…
The WeekBioPharma Dive ↗
Uncover four key misconceptions that could be holding your intensification strategies back — and how to …
The WeekSTAT News ↗
WASHINGTON — People in the food world didn’t know what to expect when the Trump administration appointed a lit…
PipelineFiercePharma ↗
With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain…
PolicyFierceBiotech ↗
As an outbreak of Ebola in central Africa continues to worsen, the federal government has tapped a little-know…
PolicyBriefing
Eli Lilly’s lawsuit claims church-affiliated pharmacies and wholesalers defrauded it through fake rebate claim…
PipelineFiercePharma ↗
According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with…
DealsFierceBiotech ↗
Medtronic has entered a deal to acquire SPR Therapeutics, a Cleveland-based company whose flagship product del…
PipelineFiercePharma ↗
A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and …
PipelineFierceBiotech ↗
A phase 2b trial of Biogen and Denali Therapeutics’ Parkinson’s disease candidate has missed its primary endpo…
PipelineBriefing
EMA’s CHMP supports AstraZeneca’s SERD camizestrant despite FDA skepticism and endorses Novo Nordisk’s first o…
PipelineEndpoints News ↗
Gilead has at long last won US approval of its hepatitis D treatment Hepcludex, which the FDA previously rejec…
PolicySTAT News ↗
The Trump administration disclosed plans to reduce state directed payments even more, setting up a probable sh…
PolicyKFF Health News ↗
This fact sheet explores the history, funding, and future outlook of the President’s Emergency Plan for AIDS R…
DealsPharmaceutical Technology ↗
The tender offer is for €51.29 per share, representing a 13% premium on Recordati’s share price before the tak…
PipelineFierceBiotech ↗
As Eli Lilly looks to hold its lead in the lucrative obesity market, the company’s next-gen prospect, the trip…
DealsFiercePharma ↗
BMS is the latest large pharma company to make a major bet on AI, announcing a sweeping agreement with Anthrop…
DealsBriefing
The Engage acquisition marks another move in Lilly’s ongoing deal blitz, targeting preclinical DNA delivery in…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.